UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1350-5
Program Prior Authorization/Notification
Medication Orgovyx™ (relugolix)
P&T Approval Date 2/2021, 2/2022, 2/2023, 2/2024, 2/2025
Effective Date 5/1/2025
1. Background:
Orgovyx (relugolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated
for the treatment of adult patients with advanced prostate cancer.
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age of
19 years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or
under some circumstances. Some states also mandate usage of other Compendium references.
Where such mandates apply, they supersede language in the benefit document or in the
notification criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Orgovyx will be approved based on the following criterion:
a. Patient is less than 19 years of age
Authorization will be issued for 12 months.
B. Prostate Cancer
1. Initial Authorization
a. Orgovyx will be approved based on the following:
(1) Diagnosis of advanced prostate cancer
Authorization will be issued for 12 months.
2. Reauthorization
a. Orgovyx will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Orgovyx
therapy
© 2025 UnitedHealthcare Services, Inc.
1
Authorization will be issued for 12 months.
C. NCCN Recommended Regimens
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a
Category of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
• Please refer to plan specifics to determine exclusion status.
4. References:
1. Orgovyx [package insert]. Marlborough, MA: Sumitomo Pharma America, Inc.; October
2024.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
https://www.nccn.org/professionals/drug_compendium/content/. Accessed December 20,
2024.
Program Prior Authorization/Notification – Orgovyx™ (relugolix)
Change Control
2/2021 New program.
2/2022 Annual review with no changes to coverage criteria. Updated
references.
2/2023 Annual review with no changes to coverage criteria. Added state
mandate footnote and updated references.
2/2024 Annual review with no changes to coverage criteria. Updated
references.
2/2025 Annual review with no changes to coverage criteria. Updated
references.
© 2025 UnitedHealthcare Services, Inc.
2